GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Future Medicine Ltd  (8)
Material
Publisher
  • Future Medicine Ltd  (8)
Person/Organisation
Language
Years
FID
  • 1
    Online Resource
    Online Resource
    Interview: Understanding the complex pathways from normal cognition to dementia: the role of neuroimaging
    Future Medicine Ltd ; 2013
    In:  Neurodegenerative Disease Management Vol. 3, No. 5 ( 2013-10), p. 413-416
    Details
    In: Neurodegenerative Disease Management, Future Medicine Ltd, Vol. 3, No. 5 ( 2013-10), p. 413-416
    Abstract: Charles DeCarli is Professor of Neurology at the University of California in Davis (CA, USA) and recipient of the Victor and Genevieve Orsi Chair in Alzheimer’s Research. He is the Director of the University of California in Davis Alzheimer’s Disease Center, an NIH-funded Alzheimer’s research center. He is also Director of the Imaging of Dementia and Aging laboratory. His research focuses on using advanced structural and functional brain imaging to study normal aging, mild cognitive impairment and dementia, as well as the role of genetics, and cerebrovascular and Alzheimer’s disease on these processes. He has published over 300 peer-reviewed journal articles in high-impact journals such as Brain, Lancet Neurology and Nature Genetics. He is a recipient of the J Allyn Taylor International Prize in Medicine–Imaging of the Aging Brain in recognition of his work. In addition, DeCarli is the Editor-in-Chief of Alzheimer Disease and Associated Disorders, an international journal of Alzheimer’s disease research.
    Type of Medium: Online Resource
    ISSN: 1758-2024 , 1758-2032
    URL: Article
    DOI: 10.2217/nmt.13.47
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2013
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    A brief discussion of aspects in breast cancer research, science mentorship and the workplace culture today
    Future Medicine Ltd ; 2017
    In:  Breast Cancer Management Vol. 6, No. 3 ( 2017-08), p. 89-96
    Details
    In: Breast Cancer Management, Future Medicine Ltd, Vol. 6, No. 3 ( 2017-08), p. 89-96
    Abstract: Balkees Abderrahman speaks to Roshaine Wijayatunga, managing commissioning editor: Balkees Abderrahman is a Fellow of Breast Medical Oncology at MD Anderson Cancer Center and a Fellow of the Royal Society of Medicine of Great Britain. She is a PhD trainee under model “Applicants of Very High Quality” at the Faculty of Medicine, The University of Leeds, West Yorkshire, Great Britain. She works with Professor V Craig Jordan, OBE, FMedSci. Dr. Abderrahman is the author of “Steroid Receptors in Breast Cancer, The Breast: Comprehensive Management of Benign and Malignant Diseases 2017”, “Hormones and Cancer, Oxford Textbook of Cancer Biology 2018”, “First Targeted Therapy – History of Tamoxifen, Estrogen Receptor and Breast Cancer, Cancer Drug Discovery and Development, Springer Nature 2018” and “Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor and Breast Cancer, Cancer Drug Discovery and Development, Springer Nature 2018”. She has published several articles in breast cancer research. She is also the author of “Love at the Gate” and “Oliver and the Rock” and a contributor at Nature, the Pharmaceutical Journal of the Royal Pharmaceutical Society of Great Britain, The Independent, The American Society of Clinical Oncology (ASCO) Post, The Huffington Post, US News and World Report, The Hill and The Nation. She was a finalist for the Outstanding Youth Award at the United Nations from over 86 countries for “Her outstanding work in tackling some of our greatest social, economic, and environmental challenges”.
    Type of Medium: Online Resource
    ISSN: 1758-1923 , 1758-1931
    URL: Article
    DOI: 10.2217/bmt-2017-0025
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2017
    detail.hit.zdb_id: 2669704-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    The role of surgery in low-grade gliomas: do timing and extent of resection matter?
    Future Medicine Ltd ; 2017
    In:  CNS Oncology Vol. 6, No. 3 ( 2017-07), p. 179-183
    Details
    In: CNS Oncology, Future Medicine Ltd, Vol. 6, No. 3 ( 2017-07), p. 179-183
    Abstract: Hugues Duffau is a Professor and Chairman of the Neurosurgery Department in the Montpellier University Medical Center and Head of the INSERM 1051 Team “plasticity of the central nervous system, human stem cells and glial tumors” at the Institute for Neurosciences of Montpellier (France). He is an expert in the awake cognitive neurosurgery of slow-growing brain tumors, such as low-grade gliomas, a routine which he has developed since 20 years. His fundamental approach is centered on the concepts of the brain connectomics and neuroplasticity, breaking with the traditional localizationist view of cerebral processing. For his innovative work in neurosurgery and neurosciences, he was awarded Doctor Honoris Causa several times, and he was the youngest recipient of the prestigious Herbert Olivecrona Award from the Karolinska Institute in Stockholm. He has written four textbooks and over 335 publications in international journals ranging from neurosurgery to fundamental neurosciences, including cognitive sciences and brain plasticity for a total of more than 20,800 citations and with an h-index of 77. He is a member of editorial boards of many journals (as brain and language, neurosurgery or neuro-oncology) and ad hoc reviewer for around 100 journals (over 900 reviews) including: New England Journal of Medicine, Lancet Oncology, Nature Medicine, Nature Reviews Neuroscience, Nature Reviews Neurology; Annals of Neurology, Brain, Cerebral Cortex, Trends in Cognitive Science, Current Biology, among others. He is a member of many societies: member of the French Academy of Medicine, member of the French Academy of Surgery, member of the World Academy of Neurological Surgery, member of the Young Neurosurgeons Award Committee of the World Federation of Neurosurgical Societies, member of the Scientific Committee of the European Association for Neuro-oncology, etc.
    Type of Medium: Online Resource
    ISSN: 2045-0907 , 2045-0915
    URL: Article
    DOI: 10.2217/cns-2017-0009
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2017
    detail.hit.zdb_id: 2692808-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Making melanoma therapy personal: an interview with Dr Keiran Smalley for Melanoma Management
    Future Medicine Ltd ; 2017
    In:  Melanoma Management Vol. 4, No. 2 ( 2017-05), p. 95-97
    Details
    In: Melanoma Management, Future Medicine Ltd, Vol. 4, No. 2 ( 2017-05), p. 95-97
    Abstract: Dr Smalley earned his PhD in Pharmacology from the University of Cambridge, UK, in 2001. He worked as a post-doctoral fellow in the Oncology Department of University College London, the Institute of Cancer Research, Fulham Road and the Wistar Institute, PA, USA. Currently, Dr Smalley is a Professor in the Departments of Tumor Biology and Cutaneous Oncology at the Moffitt Cancer Center, FL, USA. He is also currently the Donald A Adam Endowed Chair in Melanoma Research and is the Director of the Melanoma and Skin Cancers Center of Excellence. The lab of Dr Smalley focuses upon the development of targeted therapy strategies for melanoma and is currently funded by the NCI, the pharmaceutical industry and a number of philanthropic sources. Dr Smalley's work is highly translational in nature and work from his lab has led to the initiation of a number of clinical trials. To date, Dr Smalley has published over 120 papers in top peer-reviewed journals including Cancer Research, Cancer Discovery, Cancer Cell, New England Journal of Medicine, the Proceedings of the National Academy of Sciences, the Lancet, Gastroenterology and Clinical Cancer Research. He currently sits on the editorial boards of Clinical Cancer Research, Biochemical Pharmacology, Drugs, Melanoma Research and the American Journal of Clinical Dermatology and is the Associate Editor of Pharmacological Research. Dr Smalley is a charter member of the Basic Mechanisms of Cancer Therapeutics Study Section for the NCI/NIH and has served on many other peer review panels for the Department of Defense, the state of Texas and numerous melanoma research foundations. He has also fulfilled advisory roles with the University of Pennsylvania, the University of Pittsburgh and a number of pharmaceutical companies. Dr Smalley has been a visiting professor at the University of Sao Paulo, Brazil in 2011 and in 2014 received a Science Without Borders Scholarship from the Brazilian Government.
    Type of Medium: Online Resource
    ISSN: 2045-0885 , 2045-0893
    URL: Article
    DOI: 10.2217/mmt-2017-0001
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2017
    detail.hit.zdb_id: 2786852-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Introduction of our new Associate Editor
    Future Medicine Ltd ; 2014
    In:  CNS Oncology Vol. 3, No. 5 ( 2014-09), p. 327-328
    Details
    In: CNS Oncology, Future Medicine Ltd, Vol. 3, No. 5 ( 2014-09), p. 327-328
    Abstract: Annick Desjardins, MD, FRCPC, speaks to Roshaine Gunawardana, Managing Commissioning Editor: Annick Desjardins is Associate Professor within the Department of Neurology and is the Director of Clinical Research at The Preston Robert Tisch Brain Tumor Center at Duke. In 2003, Dr Desjardins completed her residency in Adult Neurology at the Universite de Sherbrooke, Quebec, Canada. Following a 2-year fellowship in neuro-oncology at The Preston Robert Tisch Brain Tumor Center at Duke, she joined the Center as faculty, in July 2005. She is a Fellow of the Royal College of Physicians of Canada. She has been the Principal Investigator on over 30 therapeutic trials in neuro-oncology, including investigator initiated and international multicenter studies, and has held several Investigational New Drug applications. She has over 80 peer-review publications and six book chapters. She has written invited expert reviews for Hospital Pharmacy Europe, Nature Reviews Neurology, Clinical Care Options and MEDscape CME. She is reviewer for Neuro-Oncology, Cancer, Journal of Neuro-Oncology, Clinical Cancer Research, Expert Review of Anticancer Therapy, Cancer Research, Molecular Cancer Therapeutics and Future Oncology.
    Type of Medium: Online Resource
    ISSN: 2045-0907 , 2045-0915
    URL: Article
    DOI: 10.2217/cns.14.32
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2014
    detail.hit.zdb_id: 2692808-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Personalizing therapy for colorectal cancer
    Future Medicine Ltd ; 2015
    In:  Colorectal Cancer Vol. 4, No. 6 ( 2015-10), p. 225-227
    Details
    In: Colorectal Cancer, Future Medicine Ltd, Vol. 4, No. 6 ( 2015-10), p. 225-227
    Abstract: Heinz-Josef Lenz speaks to Roshaine Gunawardana, Managing Commissioning Editor: Dr Heinz-Josef Lenz is Professor of Medicine and Professor of Preventive Medicine, holds the Kathryn Balakrishnan Chair for Cancer Research, is Associate Director, Clinical Research, Co-Chair of gastrointestinal (GI) Oncology, Co-Director USC Center for Molecular Pathways and Drug Discovery at the University of Southern California Keck School of Medicine and USC/Norris Comprehensive Cancer Center in Los Angeles (CA, USA). Dr Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz (Germany), and went on to complete a residency in hematology and oncology at the Eberhard-Karls Universität Tübingen (Germany), before completing clerkships in oncology and hematology at George Washington University (DC, USA) and the Beth Israel Hospital of Harvard Medical School (MA, USA), respectively. He completed a postdoctoral Fellowship in the Department of Biochemistry and Molecular Biology at the USC Keck School of Medicine. Dr Lenz's research focus is in the identification of predictive and prognostic biomarkers in GI cancers, early drug development and novel clinical trials. He is Co-Chair of SWOG GI Committee, Chair SWOG GI Translational Medicine and member of the National Cancer Institute (NCI) GI Steering Committee, NCI Investigational Drug Steering Committee, the NCI Gastroesophageal Task Force and NCI Correlative Science Committee. He is the Principal Investigator for R01, U01, U10 and USC PI for N01. He has been awarded a number of prestigious awards including American Society of Clinical Oncology (ASCO) Young Investigator Award, ASCO Career Development Award, NCI Career Development Award, STOP Cancer Career Development Award and Research Recognition Award. He has published over 270 peer reviewed papers including Nature Medicine, Nature Genetics, Journal of Clinical Oncology and Lancet.
    Type of Medium: Online Resource
    ISSN: 1758-194X , 1758-1958
    URL: Article
    DOI: 10.2217/crc.15.30
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2015
    detail.hit.zdb_id: 2669713-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Interview: Acute myeloid leukemia patient genome interview
    Future Medicine Ltd ; 2009
    In:  Personalized Medicine Vol. 6, No. 6 ( 2009-11), p. 621-622
    Details
    In: Personalized Medicine, Future Medicine Ltd, Vol. 6, No. 6 ( 2009-11), p. 621-622
    Abstract: The anonymous patient (AML2) who took part in this interview is one of approximately 180 patients that Dr Timothy J Ley from the Washington University School of Medicine (St. Louis, MO, USA) and his leukemia colleagues accrued for their study investigating the genetics of acute myeloid leukemia (AML) from the beginning of the year 2000. His team of researchers used a fledgling PCR-based re-sequencing pipeline to target and sequence various suspect/candidate genes in AML. However, this search for new genes that are frequently mutated in AML proved to be largely unsuccessful and led to the notion of whole-genome re-sequencing (e.g., that of an unbiased look at all genes and structural changes). Therefore, the sequencing of this interviewee’s genome followed the researchers’ first AML genome case, published in Nature on 6 November 2008 [1] , and since the first patient that they sequenced was a female (now deceased of her disease), they decided to choose a male patient in remission from the disease but with the same AML subtype (M1). Hence, AML2 was sequenced and analyzed – they identified recurring mutations that may be relevant for the pathogenesis of the disease. They subsequently published their results in the New England Journal of Medicine on 10 September 2009 [2] . The ultimate goal of their research is to change the ‘standard of care’ for AML patients, since for the last 25 years, doctors have been treating every AML patient in basically the same way, never knowing who will respond and go into remission, or who will not respond and will need a bone marrow transplant.
    Type of Medium: Online Resource
    ISSN: 1741-0541 , 1744-828X
    URL: Article
    DOI: 10.2217/pme.09.56
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2009
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Plain language summary: How the Pompe Registry is helping to identify and explain gene changes in Pompe disease
    Future Medicine Ltd ; 2022
    In:  Future Rare Diseases Vol. 2, No. 4 ( 2022-12)
    Details
    In: Future Rare Diseases, Future Medicine Ltd, Vol. 2, No. 4 ( 2022-12)
    Abstract: This is a summary of an article originally published in the journal Human Mutation. Pompe disease is a rare genetic disorder. In the USA, one person in every 10,000 to 28,000 people is born with Pompe disease. Pompe disease develops when both parents pass on a copy of a gene, called GAA, that has a disease-causing change to it. The GAA gene contains the instructions to make an enzyme called acid alpha glucosidase; abbreviated as ‘GAA’, which breaks down glycogen into glucose. When the GAA gene contains a disease-causing change, this can lead to a total absence of GAA or the enzyme failing to function properly. As a result, glycogen builds up in cells and causes damage to organs such as the heart and muscles. There is a wide range of severity and symptoms in Pompe disease, including muscle weakness, heart and breathing issues, and extreme tiredness (fatigue). There are many changes in the GAA gene (called variants) that can result in Pompe disease. The severity of symptoms and when symptoms start partly depend on the variants that the people with Pompe disease have inherited from their parents. What was learned & how? Researchers looked at GAA gene variants from people with Pompe disease using a database called the Pompe Registry. Since 2004, the Pompe Registry has collected worldwide clinical information on people with Pompe disease and their gene changes. The researchers investigated how many different GAA variants are currently listed in this registry, and how common each variant was overall and in different geographical regions. The researchers assigned the people to three groups based on the age of when their symptoms began and if they had an enlarged heart diagnosed in their first year of life. Out of 1753 people enrolled in the Pompe Registry, the researchers analyzed data from 1079 people from 26 countries. 2075 GAA gene variants were identified, 80 of which had not been reported before. A harmful variant called c.-32-13T 〉 G was the most common overall and was present in North America, Latin America and Europe. What are the practical implications? This analysis supports healthcare professionals and people with Pompe disease to appreciate the geographic distribution and to assess the nature of GAA variants. The findings can help with the diagnosis of Pompe disease and the understanding of how different variants relate to the start and severity of symptoms. This information will also help genetic counsellors and doctors to have discussions with people with Pompe disease and their families and caregivers about genetic risk and family planning. Clinical Trial Registration: NCT00231400 ( ClinicalTrials.gov )
    Type of Medium: Online Resource
    ISSN: 2399-5262 , 2399-5270
    URL: Article
    DOI: 10.2217/frd-2022-0009
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...